Autoimmune neurologic disorders are more common than previously thought. Currently, traditional immunotherapies are the mainstay of the treatment for autoimmune neurologic disorders. Immunotherapies are not without risk, and the treating neurologist should always be cognizant of the associated complications of long-term immunotherapy. Prospective trials are needed to further define the best treatment approach to these potentially reversible disorders. Committed to novel therapeutic strategy development of autoimmune neurological disorders for years, Creative Biolabs has accumulated precious experience from every step we paid during the research. We have also established a comprehensive platform to provide global researchers with high-quality antibody development and cell therapy services.
Autoimmune neurological disorders often have multifocal symptoms and typically present subacutely. Multiple structures in the central and peripheral nervous system can be targets of pathogenic autoantibodies, resulting in diverse clinical presentations. Central nervous system (CNS) manifestations include neuropsychiatric symptoms, encephalopathy, seizures, catatonia, chorea, sleep disorders, myoclonus, opsoclonus, optic neuritis, stiff person syndrome, cerebellar ataxia, brainstem syndromes, and myelopathy. Peripheral nervous system symptoms include radiculopathy, plexopathy, neuronopathy, peripheral neuropathy, neuromuscular junction, and muscle disorders. Autonomic nervous system manifestations include anhidrosis, difficulty transitioning from dark to light, orthostasis, cardiac arrhythmias, gastrointestinal dysmotility, and urologic dysfunction.
Fig.1 Venn diagram of the relationship between neurological, psychotic, and autoimmune disorders. (Mane-Damas, 2019)
At present, the treatment of antibody-associated autoimmune neurologic disorders is based on recommendations from expert opinion and information from available case reports and case series. The goal of immunotherapy is to provide the maximum response, reducing nervous system inflammation and decreasing symptoms, maintaining improvements by preventing relapses and minimize side effects. Following antibody titers in the management of patients has several limitations and rarely helps guide therapy, which should be based on clinical findings as titers are not reliable markers of disease severity, but they can sometimes predict relapses and support the use of prolonged immunotherapy for prevention.
Focus on autoimmune neurological disorders for years, Creative Biolabs is professional in cell therapy, drug, and antibody development of many autoimmune neurological diseases including:
|Acute Disseminated Encephalomyelitis (ADEM)
|Multiple Sclerosis (MS)
|Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
|Guillain-Barre Syndrome (GBS)
Our services including but not limited to:
With high incidence and lack of therapeutic strategies, autoimmune neurological disorders are very important in research. With extensive experience and a professional platform, Creative Biolabs is capable of providing high-quality drug development services to global researchers. If you have any questions or are interested in our services, please feel free to contact us for more information.
For Research Use Only | Not For Clinical Use